Mint Pharmaceuticals Inc. is pleased to announce the expansion of its distribution partnership with Bayer Inc. to include ANGELIQ (drospirenone and estradiol-17β tablets), CLIMARA 25, CLIMARA 50 and CLIMARA 75 (estradiol hemihydrate transdermal systems), TRIQUILAR 21 and TRIQUILAR 28 (levonorgestrel and ethinyl estradiol tablets), and XARELTO (rivaroxaban granules for oral suspension) in Canada. The expanded collaboration builds on the companies' existing relationship and shared commitment to reliable access to medicines for Canadian patients and healthcare professionals.
"Ensuring Canadian patients and healthcare professionals can rely on consistent access to established medicines is central to Mint's mission," said Jaiveer Singh, Chief Executive Officer of Mint Pharmaceuticals. "Expanding our work with Bayer allows us to apply Mint's resilient supply chain and nationwide distribution capabilities across a broader portfolio, while advancing our mutual focus on reliability, quality and patient care."
"We are pleased to expand our partnership with Mint Pharmaceuticals Inc., building on a trusted collaboration rooted in quality, reliability and a shared commitment to patient care," said Viktoria Friedrich, President and CEO of Bayer Inc. in Canada. "By broadening this partnership across additional Bayer medicines, we can continue to leverage Mint's strong Canadian distribution network and market expertise to help ensure these treatments remain accessible to healthcare professionals and patients who rely on them."